Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol as Adjuvant Therapy in Generalized Myasthenia Gravis
NCT03914638Phase 3Unknown
- Sponsor
- Aarhus University
- Start
- Apr 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salbutamol in myasthenia gravis (MG) (2 arms), sponsored by Aarhus University. Primary endpoints: Myasthenia Gravis Quality of Life 15-items at 8 weeks and Treatment Tolerability at 8 weeks. Status: unknown.
02
Drugs
salbutamol
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03914638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914638.